AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. is a global, research-driven biopharmaceutical company operating as a single business segment with leadership positions in immunology, neuroscience, oncology, aesthetics, eye care and other specialty therapeutics. Its portfolio includes major brands such as Skyrizi, Rinvoq, Humira, Vraylar, Imbruvica, Venclexta, Botox Cosmetic and Juvederm.
Skyrizi and Rinvoq are now central growth drivers, together accounting for approximately 42% of AbbVie’s total net revenues in 2025. The company emphasizes proprietary biologics and complex therapies, supported by substantial research and development, extensive global manufacturing, and broad marketing and distribution capabilities across more than 70 countries.
AbbVie highlights significant risks, including loss of exclusivity and biosimilar or generic competition, particularly for key biologics; pricing and reimbursement pressure globally, including U.S. Medicare reforms under the Inflation Reduction Act that will impose government-set prices on products such as Imbruvica, Vraylar, Linzess and Botox; and potential challenges to its extensive patent portfolio. The company also notes regulatory, environmental and supply-chain obligations and relies on collaborations, third‑party manufacturers and raw-material suppliers to support operations.
AbbVie Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and full year ended December 31, 2025. The company released these results on February 4, 2026, and attached the full press release as Exhibit 99.1.
The filing is presented under the Results of Operations and Financial Condition section, indicating the update relates to AbbVie’s operating performance and overall financial health for 2025. Detailed figures and metrics are contained in the referenced press release rather than in this summary document.
AbbVie Inc. updated its earnings outlook to reflect a large research and development charge in the fourth quarter of 2025. The company expects acquired in-process R&D and milestones expense of $1.3 billion on a pre-tax basis, which is estimated to reduce both GAAP diluted EPS and adjusted non-GAAP diluted EPS by $0.71 per share for the quarter.
Including this fourth quarter expense, AbbVie now expects its full-year 2025 adjusted diluted EPS to be in the range of $9.90–$9.94. For the fourth quarter of 2025, adjusted diluted EPS is guided to a range of $2.61–$2.65. The company notes that results for the quarter ended December 31, 2025 are preliminary and subject to completion of its financial closing procedures.
AbbVie Inc. director Robert J. Alpern reported a routine compensation-related transaction. On 12/31/2025, he acquired 34 stock equivalent units tied to AbbVie common stock at $228.49 per unit, bringing his total holdings of these derivative securities to 10,257 stock equivalent units.
According to the disclosure, these units represent director fees credited to stock equivalent unit accounts under grantor trusts established at Abbott Laboratories and AbbVie. The units are paid out in cash, generally at age 65 or upon retirement from each company’s board, and earn the same return as if the fees were invested in AbbVie stock. The reported balance also reflects units acquired through a dividend reinvestment feature.
AbbVie Inc. director equity filing: A Form 4 reports that a director of AbbVie received 68 stock equivalent units on 12/31/2025 at a reference value of $228.49 per unit. These units are credited as director fees into a stock equivalent unit account in a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board. After this transaction, the director beneficially owns 707 stock equivalent units, which are designed to earn the same return as if the fees were invested directly in AbbVie common stock, including through a dividend reinvestment feature.
AbbVie Inc. director Edward J. Rapp reported an acquisition of stock equivalent units tied to AbbVie stock. On 12/31/2025, 147 stock equivalent units were credited at a price of $228.49 per unit, bringing his total directly held derivative securities reported on this form to 28,498 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are paid in cash generally at age 65 or upon retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the reported balance includes units acquired through a dividend reinvestment feature.
AbbVie Inc. reported Q3 2025 results. Net revenues were $15,776 million, up from $14,460 million a year ago, while operating earnings fell to $1,904 million from $3,831 million as the company recorded significant charges. Net earnings were $186 million and diluted EPS was $0.10.
Results reflect acquired IPR&D and milestones expense of $2,680 million in the quarter and intangible asset impairments of $847 million in cost of products sold tied to Resonic and Durysta. Interest expense, net, was $667 million. For the nine months ended September 30, 2025, net revenues were $44,542 million and net earnings were $2,410 million; operating cash flow was $13,812 million.
AbbVie completed or announced portfolio moves: Capstan Therapeutics (cash consideration of $2.1 billion; $1.9 billion recognized in IPR&D), Ichnos Glenmark ISB-2001 license (upfront $700 million), ADARx options (upfront $335 million), Gubra license (upfront $350 million), Nimble Therapeutics acquisition (aggregate $288 million). Subsequent to quarter end, AbbVie acquired Gilgamesh Pharmaceuticals for approximately $900 million upfront. Total equity was a deficit of $2,599 million as of September 30, 2025.
AbbVie Inc. (ABBV) filed an 8-K announcing Q3 2025 results. The company issued a press release for the third quarter ended September 30, 2025, and furnished it with this report.
The press release is included as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). No financial figures are detailed in this report itself.
AbbVie Inc. filed a Form 8-K to update investors on how acquired in-process research and development (IPR&D) and milestone expenses will affect its 2025 earnings. For the third quarter of 2025, AbbVie expects to record $2.7 billion of acquired IPR&D and milestones expense on a pre-tax basis, which it says will have an unfavorable impact of $1.50 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. The company notes that results for the quarter ended September 30, 2025 are still preliminary and may change.
AbbVie reiterates that it does not forecast acquired IPR&D and milestones expense because the timing and occurrence of such transactions are uncertain, and prior 2025 guidance excluded these expenses beyond the second quarter. Including the third quarter 2025 acquired IPR&D and milestones expense, AbbVie now provides a full-year 2025 adjusted diluted earnings per share guidance range of $10.38 to $10.58, and a third quarter 2025 adjusted diluted earnings per share guidance range of $1.74 to $1.78.
Susan E. Quaggin, an AbbVie Inc. (ABBV) director, had 67 stock equivalent units credited to her account on 09/30/2025 at a unit value of $231.54. The filing shows these units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board; they earn returns as if invested in AbbVie stock. The report indicates a post-transaction beneficial ownership balance of 634 shares (including units acquired through a dividend reinvestment feature).